Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Very Early Onset of Amiodarone-Induced Pulmonary Toxicity

  • Lee, Wonho (Department of Internal Medicine, Kangwon National University Hospital) ;
  • Ryu, Dong Rueol (Department of Internal Medicine, Kangwon National University Hospital) ;
  • Han, Seon-Sook (Department of Internal Medicine, Kangwon National University Hospital) ;
  • Ryu, Sook-Won (Department of Laboratory Medicine, Kangwon National University Hospital) ;
  • Cho, Byung Ryul (Department of Internal Medicine, Kangwon National University Hospital) ;
  • Kwon, Hyucki (Department of Internal Medicine, Kangwon National University Hospital) ;
  • Kim, Bo Ra (Department of Internal Medicine, Kangwon National University Hospital)
  • Published : 2013.10.31
⟨ Previous Next ⟩

Abstract

Amiodarone is a widely used antiarrhythmic agent. Among its various adverse effects, amiodarone-induced pulmonary toxicity (APT) is the most life threatening complication, which has been described mostly in patients who have been in treatment with high accumulative doses for a long duration of time. However, amiodarone therapy in short-term duration induced APT was rarely reported. We describe a case of a 54-year-old man who is presented with symptoms of APT after a few days of therapy for post-myocardial infarction ventricular tachycardia. For early diagnosis and successful treatment, awareness and high suspicion of this rare type of early onset APT is crucial in patients with amiodarone therapy.

Keywords

References

  1. Dusman RE, Stanton MS, Miles WM, et al. Clinical features of amiodarone- induced pulmonary toxicity. Circulation 1990;82:51-9. https://doi.org/10.1161/01.CIR.82.1.51
  2. Martin WJ 2nd, Rosenow EC 3rd. Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part I). Chest 1988;93:1067-75. https://doi.org/10.1378/chest.93.5.1067
  3. Martin WJ 2nd, Rosenow EC 3rd. Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part 2). Chest 1988;93:1242-8. https://doi.org/10.1378/chest.93.6.1242
  4. Ernawati DK, Stafford L, Hughes JD. Amiodarone-induced pulmonary toxicity. Br J Clin Pharmacol 2008;66:82-7. https://doi.org/10.1111/j.1365-2125.2008.03177.x
  5. Jang WJ, Chon HR, Jung JS, et al. Amiodarone-induced pulmonary toxicity within a short period of the initiation of amiodarone therapy: a case report. Korean J Crit Care Med 2011;26:117-21. https://doi.org/10.4266/kjccm.2011.26.2.117
  6. Tanawuttiwat T, Harindhanavudhi T, Hanif S, Sahloul MZ. Amiodarone-induced alveolar haemorrhage: a rare complication of a common medication. Heart Lung Circ 2010;19:435-7. https://doi.org/10.1016/j.hlc.2010.01.008
  7. Papiris SA, Triantafillidou C, Kolilekas L, Markoulaki D, Manali ED. Amiodarone: review of pulmonary effects and toxicity. Drug Saf 2010;33:539-58. https://doi.org/10.2165/11532320-000000000-00000

Cited by

  1. Amiodarone : Pulmonary toxicity: case report vol.1483, pp.1, 2014, https://doi.org/10.1007/s40278-014-7860-1
  2. Vernakalant hydrochloride to treat atrial fibrillation vol.15, pp.6, 2013, https://doi.org/10.1517/14656566.2014.898751
  3. High-resolution sub-cellular imaging by correlative NanoSIMS and electron microscopy of amiodarone internalisation by lung macrophages as evidence for drug-induced phospholipidosis vol.53, pp.9, 2013, https://doi.org/10.1039/c6cc08549k
  4. A nontrivial differential diagnosis in COVID-19 pandemic: a case report and literary review of amiodarone-induced interstitial pneumonia vol.17, pp.6, 2013, https://doi.org/10.2217/fca-2020-0168